Apellis Pharmaceuticals

Apellis cites current challenges with Syfovre launch but bright prospects in the long term
Fierce Pharma
Wed, 02/28/24 - 09:42 pm
Apellis Pharmaceuticals
drug launches
geographic atrophy
Syfovre
Apellis to lay off 25% of staff, trim research in major restructuring
BioPharma Dive
Tue, 08/29/23 - 11:27 am
Apellis Pharmaceuticals
restructuring
layoffs
Apellis Eye Injection Treatment Flagged for Safety Issues
BioSpace
Mon, 07/31/23 - 11:34 am
Apellis Pharmaceuticals
Syfovre
retinal vasculitis
drug safety
Experts flag eye inflammation reports tied to Apellis' geographic atrophy med Syfovre
Fierce Pharma
Tue, 07/18/23 - 11:23 am
Apellis Pharmaceuticals
Syfovre
geographic atrophy
side effects
Apellis abandons ALS drug after study miss
BioPharma Dive
Thu, 05/25/23 - 01:16 pm
Apellis Pharmaceuticals
ALS
clinical trials
pegcetacoplan
2023’s biggest launches: the story so far
EP Vantage
Fri, 05/12/23 - 10:19 am
drug launches
AbbVie
Almirall
Apellis Pharmaceuticals
Astellas
AstraZeneca
Biogen
CRISPR Therapeutics
Daiichi Sankyo
Eli Lilly
Genmab
GSK
Iveric Bio
Pfizer
Roche
SAGE Therapeutics
Sanofi
Sarepta Therapeutics
Shionogi
Swedish Orphan Biovitrum
Vertex Pharmaceuticals
Apellis reports strong start for new vision loss drug
BioPharma Dive
Mon, 05/8/23 - 10:05 am
Apellis Pharmaceuticals
Syfovre
geographic atrophy
Apellis’ immune system drug hits a setback in ALS
BioPharma Dive
Mon, 04/24/23 - 10:12 am
Apellis Pharmaceuticals
clinical trials
ALS
pegcetacoplan
Biopharma stocks go back to bleak
EP Vantage
Thu, 04/6/23 - 09:51 am
Albireo Pharma
Amryt Pharma
Apellis Pharmaceuticals
AstraZeneca
BridgeBio
Novo Nordisk
Pfizer
Protagonist Therapeutics
Provention Bio
Reata Pharmaceuticals
Regeneron
Sanofi
Seagen
Go or no go? Vaccines and neurology up for discussion
EP Vantage
Tue, 02/28/23 - 11:05 am
FDA
Acadia Pharmaceuticals
Apellis Pharmaceuticals
AstraZeneca
Biogen
Biomarin
Cidara Therapeutics
Emergent BioSolutions
GSK
Incyte
Ionis Pharmaceuticals
Melinta Therapeutics
Mundipharma
Novartis
Pfizer
Pharming
Regeneron
Roche
vaccines
RSV
ALS
COVID-19
FDA accepts Iveric Bio's NDA, grants priority review for GA drug
Endpoints
Tue, 02/21/23 - 10:12 am
Iveric Bio
FDA
geographic atrophy
Apellis Pharmaceuticals
avacincaptad pegol
FDA Approves Apellis' Syfovre as First Treatment for Geographic Atrophy
BioSpace
Mon, 02/20/23 - 12:22 pm
Apellis Pharmaceuticals
Syfovre
pegcetacoplan
FDA
geographic atrophy
Apellis Pharmaceuticals Surges On New Review Date For Eye-Disease Treatment
Investors Business Daily
Fri, 11/18/22 - 11:30 am
Apellis Pharmaceuticals
pegcetacoplan
eye disease
geographic atrophy
Iveric hits again in pivotal eye disease program, keeping it on Apellis' tail in race to market
Fierce Biotech
Tue, 09/6/22 - 10:41 am
Iveric Bio
Apellis Pharmaceuticals
clinical trials
FDA
dry eye disease
geographic atrophy
Brace for an end-of-year boost to drug approvals
EP Vantage
Fri, 09/2/22 - 12:14 pm
FDA
drug approvals
Alnylam Pharmaceuticals
Apellis Pharmaceuticals
Bristol Myers Squibb
Eli Lilly
Gilead Sciences
Mirati Therapeutics
Moderna Therapeutics
Provention Bio
Roche
TG Therapeutics
Travere Therapeutics
Apellis Surges By Double Digits As FDA Mulls Its Eye-Disease Treatment
Investors Business Daily
Tue, 07/19/22 - 10:14 am
Apellis Pharmaceuticals
geographic atrophy
FDA
pegcetacoplan
Apellis' eye med application on track for next year after FDA OKs inclusion of phase 2 data
Fierce Pharma
Mon, 11/15/21 - 11:51 pm
Apellis Pharmaceuticals
pegcetacoplan
FDA
clinical trials
age-related macular degeneration
Apellis eye drug succeeds in one key study, but falls short in its twin
BioPharma Dive
Thu, 09/9/21 - 11:16 pm
Apellis Pharmaceuticals
FDA
pegcetacoplan
geographic atrophy
Apellis set to take on Alexion as FDA clears PNH drug Empaveli
Pharmaforum
Mon, 05/17/21 - 10:39 am
Apellis Pharmaceuticals
Alexion
Empaveli
FDA
PNH
Apellis stops COVID-19 program after missing mortality endpoint
Fierce Biotech
Fri, 03/5/21 - 10:37 am
Apellis Pharmaceuticals
APL-9
COVID-19
clinical trials

Pages